233 related articles for article (PubMed ID: 1503449)
1. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.
Fu KP; Lafredo SC; Foleno B; Isaacson DM; Barrett JF; Tobia AJ; Rosenthale ME
Antimicrob Agents Chemother; 1992 Apr; 36(4):860-6. PubMed ID: 1503449
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Dholakia N; Rolston KV; Ho DH; LeBlanc B; Bodey GP
Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Iyer P
J Antimicrob Chemother; 1995 Jun; 35(6):805-19. PubMed ID: 7559192
[TBL] [Abstract][Full Text] [Related]
5. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.
Yamane N; Jones RN; Frei R; Hoban DJ; Pignatari AC; Marco F
J Chemother; 1994 Apr; 6(2):83-91. PubMed ID: 8077990
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.
Fung-Tomc J; Desiderio JV; Tsai YH; Warr G; Kessler RE
Antimicrob Agents Chemother; 1989 Jun; 33(6):906-14. PubMed ID: 2764541
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
Gargallo-Viola D; Esteve M; Llovera S; Roca X; Guinea J
Antimicrob Agents Chemother; 1991 Mar; 35(3):442-7. PubMed ID: 2039195
[TBL] [Abstract][Full Text] [Related]
9. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Nakamura S; Minami A; Nakata K; Kurobe N; Kouno K; Sakaguchi Y; Kashimoto S; Yoshida H; Kojima T; Ohue T
Antimicrob Agents Chemother; 1989 Aug; 33(8):1167-73. PubMed ID: 2802544
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of ofloxacin and its mode of action.
Sato K; Inoue Y; Fujii T; Aoyama H; Mitsuhashi S
Infection; 1986; 14 Suppl 4():S226-30. PubMed ID: 3028966
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.
Gargallo-Viola D; Ferrer S; Tudela E; Robert M; Coll R; Roser R; Guinea J
Antimicrob Agents Chemother; 2001 Nov; 45(11):3113-21. PubMed ID: 11600365
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
16. E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.
Guinea J; Gargallo-Viola D; Robert M; Tudela E; Xicota MA; Garcia J; Esteve M; Coll R; Pares M; Roser R
Antimicrob Agents Chemother; 1995 Feb; 39(2):413-21. PubMed ID: 7726507
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
Arpi M; Gahrn-Hansen B; Søgaard P; Bentzon MW
Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.
Gesu GP; Marchetti F; Piccoli L; Cavallero A
Antimicrob Agents Chemother; 2003 Feb; 47(2):816-9. PubMed ID: 12543701
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
